First Rounders

Chad Womack is senior director of STEM initiatives at UNCF. The episode covers Womack's path to HIV research at Harvard, his experience founding a biotech just before the Great Recession, and what the election of President Barack Obama meant to African Americans.

Hosted on Acast. See acast.com/privacy for more information.

Chad Womack is senior director of STEM initiatives at UNCF. The episode covers Womack's path to HIV research at Harvard, his experience founding a biotech just before the Great Recession, and what the election of President Barack Obama meant to African Americans. For information regarding your data privacy, visit acast.com/privacy

Christoph Lengauer is a venture partner at Third Rock Ventures, the president of Celsius Therapeutics, and executive vice president at Blueprint Medicines. His conversation with Nature Biotechnology covers growing up in Austria, why he nearly gave up research for a career helping settle refugees, and his role in the Henrietta Lacks story.

Hosted on Acast. See acast.com/privacy for more information.

Christoph Lengauer is a venture partner at Third Rock Ventures, the president of Celsius Therapeutics, and executive vice president at Blueprint Medicines. His conversation with Nature Biotechnology covers growing up in Austria, why he nearly gave up research for a career helping settle refugees, and his role in the Henrietta Lacks story. For information regarding your data privacy, visit acast.com/privacy

Feng Zhang runs the Zhang Lab at the Massachusetts Institute of Technology. He's also a faculty member at the Broad Institute of MIT and Harvard, and has co-founded several biotech companies, including Editas Medicine. His conversation with Nature Biotechnology covers immigrating to America as a boy, his moment of discovery with CRISPR, and what massive success before the age of 35 does to a researcher.

Hosted on Acast. See acast.com/privacy for more information.

Feng Zhang runs the Zhang Lab at the Massachusetts Institute of Technology. He's also a faculty member at the Broad Institute of MIT and Harvard, and has co-founded several biotech companies, including Editas Medicine. His conversation with Nature Biotechnology covers immigrating to America as a boy, his moment of discovery with CRISPR, and what massive success before the age of 35 does to a researcher. For information regarding your data privacy, visit acast.com/privacy

John Maraganore is CEO of Alnylam Pharmaceuticals. In his talk with Nature Biotechnology he discusses his decade at Biogen, running an RNAi company when skepticism covered the field, and growing up the son of Greek immigrants in Chicago.

Hosted on Acast. See acast.com/privacy for more information.

John Maraganore is CEO of Alnylam Pharmaceuticals. In his talk with Nature Biotechnology he discusses his decade at Biogen, running an RNAi company when skepticism covered the field, and growing up the son of Greek immigrants in Chicago. For information regarding your data privacy, visit acast.com/privacy

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.

Hosted on Acast. See acast.com/privacy for more information.

Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early. For information regarding your data privacy, visit acast.com/privacy